<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28933629</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>06</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1554-8635</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Oct</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Autophagy</Title>
          <ISOAbbreviation>Autophagy</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.</ArticleTitle>
        <Pagination>
          <StartPage>1767</StartPage>
          <EndPage>1781</EndPage>
          <MedlinePgn>1767-1781</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15548627.2017.1356977</ELocationID>
        <Abstract>
          <AbstractText>Impairment in macroautophagy/autophagy flux and inflammasome activation are common characteristics of nonalcoholic steatohepatitis (NASH). Considering the lack of approved agents for treating NASH, drugs that can enhance autophagy and modulate inflammasome pathways may be beneficial. Here, we investigated the novel mechanism of ezetimibe, a widely prescribed drug for hypercholesterolemia, as a therapeutic option for ameliorating NASH. Human liver samples with steatosis and NASH were analyzed. For in vitro studies of autophagy and inflammasomes, primary mouse hepatocytes, human hepatoma cells, mouse embryonic fibroblasts with Ampk or Tsc2 knockout, and human or primary mouse macrophages were treated with ezetimibe and palmitate. Steatohepatitis and fibrosis were induced by feeding Atg7 wild-type, haploinsufficient, and knockout mice a methionine- and choline-deficient diet with ezetimibe (10 mg/kg) for 4 wk. Human livers with steatosis or NASH presented impaired autophagy with decreased nuclear TFEB and increased SQSTM1, MAP1LC3-II, and NLRP3 expression. Ezetimibe increased autophagy flux and concomitantly ameliorated lipid accumulation and apoptosis in palmitate-exposed hepatocytes. Ezetimibe induced AMPK phosphorylation and subsequent TFEB nuclear translocation, related to MAPK/ERK. In macrophages, ezetimibe blocked the NLRP3 inflammasome-IL1B pathway in an autophagy-dependent manner and modulated hepatocyte-macrophage interaction via extracellular vesicles. Ezetimibe attenuated lipid accumulation, inflammation, and fibrosis in liver-specific Atg7 wild-type and haploinsufficient mice, but not in knockout mice. Ezetimibe ameliorates steatohepatitis by autophagy induction through AMPK activation and TFEB nuclear translocation, related to an independent MTOR ameliorative effect and the MAPK/ERK pathway. Ezetimibe dampens NLRP3 inflammasome activation in macrophages by modulating autophagy and a hepatocyte-driven exosome pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Soo Hyun</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Gyuri</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>b Department of Medicine, Samsung Medical Center , Sungkyunkwan University School of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>c Graduate School , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Dai Hoon</ForeName>
            <Initials>DH</Initials>
            <AffiliationInfo>
              <Affiliation>d Department of Surgery , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Milim</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Irene</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Bohkyung</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Kook Hwan</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
              <Affiliation>e Severance Biomedical Science Institute, Yonsei Biomedical Research Institute , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Young-Mi</ForeName>
            <Initials>YM</Initials>
            <AffiliationInfo>
              <Affiliation>f Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital , University of Toronto , Toronto , Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoo</LastName>
            <ForeName>Jeong Eun</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>g Department of Pathology , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hye Jin</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>h Department of Pharmacology , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bae</LastName>
            <ForeName>Soo Han</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>e Severance Biomedical Science Institute, Yonsei Biomedical Research Institute , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Yong-Ho</ForeName>
            <Initials>YH</Initials>
            <Identifier Source="ORCID">0000-0002-6219-4942</Identifier>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>c Graduate School , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>i Institute of Endocrine Research , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Byung-Wan</ForeName>
            <Initials>BW</Initials>
            <Identifier Source="ORCID">0000-0002-9899-4992</Identifier>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>c Graduate School , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>i Institute of Endocrine Research , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Eun Seok</ForeName>
            <Initials>ES</Initials>
            <Identifier Source="ORCID">0000-0002-0364-4675</Identifier>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>c Graduate School , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>i Institute of Endocrine Research , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cha</LastName>
            <ForeName>Bong-Soo</ForeName>
            <Initials>BS</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>c Graduate School , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>i Institute of Endocrine Research , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Myung-Shik</ForeName>
            <Initials>MS</Initials>
            <Identifier Source="ORCID">0000-0003-3292-1720</Identifier>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>e Severance Biomedical Science Institute, Yonsei Biomedical Research Institute , Yonsei University College of Medicine , Seoul , Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>09</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Autophagy</MedlineTA>
        <NlmUniqueID>101265188</NlmUniqueID>
        <ISSNLinking>1554-8627</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C502661">Atg7 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051778">Basic Helix-Loop-Helix Leucine Zipper Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C484068">Tcfeb protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.2.1.45</RegistryNumber>
          <NameOfSubstance UI="D000071193">Autophagy-Related Protein 7</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EOR26LQQ24</RegistryNumber>
          <NameOfSubstance UI="D000069438">Ezetimibe</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071193" MajorTopicYN="N">Autophagy-Related Protein 7</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051778" MajorTopicYN="N">Basic Helix-Loop-Helix Leucine Zipper Transcription Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069438" MajorTopicYN="N">Ezetimibe</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005234" MajorTopicYN="N">Fatty Liver</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">NASH</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">exosome</Keyword>
        <Keyword MajorTopicYN="N">inflammasome</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28933629</ArticleId>
        <ArticleId IdType="pmc">PMC5640190</ArticleId>
        <ArticleId IdType="doi">10.1080/15548627.2017.1356977</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Musso G, Cassader M, Gambino R. 
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discovery. 2016;15:249-74. PMID:26794269</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26794269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. 
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology (Baltimore, Md). 2012;55:2005-23. doi:10.1002/hep.25762. PMID:22488764</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.25762</ArticleId>
            <ArticleId IdType="pubmed">22488764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Day CP, James OF. 
Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842-5. doi:10.1016/S0016-5085(98)70599-2. PMID:9547102</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0016-5085(98)70599-2</ArticleId>
            <ArticleId IdType="pubmed">9547102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birkenfeld AL, Shulman GI. 
Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology (Baltimore, Md). 2014;59:713-23. doi:10.1002/hep.26672. PMID:23929732</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26672</ArticleId>
            <ArticleId IdType="pmc">PMC3946772</ArticleId>
            <ArticleId IdType="pubmed">23929732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, et al.. 
Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PloS One. 2010;5:e13577. doi:10.1371/journal.pone.0013577. PMID:21042596</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0013577</ArticleId>
            <ArticleId IdType="pmc">PMC2962651</ArticleId>
            <ArticleId IdType="pubmed">21042596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quan W, Lee MS. 
Role of autophagy in the control of body metabolism. Endocrinol Metab (Seoul, Korea). 2013;28:6-11. doi:10.3803/EnM.2013.28.1.6. PMID:24396643</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3803/EnM.2013.28.1.6</ArticleId>
            <ArticleId IdType="pmc">PMC3811796</ArticleId>
            <ArticleId IdType="pubmed">24396643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amir M, Czaja MJ. 
Autophagy in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2011;5:159-66. doi:10.1586/egh.11.4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/egh.11.4</ArticleId>
            <ArticleId IdType="pmc">PMC3104297</ArticleId>
            <ArticleId IdType="pubmed">21476911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, Maurice N, Mukherjee A, Goldbach C, Watkins S, et al.. 
An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science (New York, NY). 2010;329:229-32. doi:10.1126/science.1190354</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1190354</ArticleId>
            <ArticleId IdType="pubmed">20522742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, Hoffman HM, Feldstein AE. 
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology (Baltimore, Md). 2014;59:898-910. doi:10.1002/hep.26592. PMID:23813842</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26592</ArticleId>
            <ArticleId IdType="pmc">PMC4008151</ArticleId>
            <ArticleId IdType="pubmed">23813842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauernfeind F, Ablasser A, Bartok E, Kim S, Schmid-Burgk J, Cavlar T, Hornung V. 
Inflammasomes: current understanding and open questions. Cell Mol Life Sci. 2011;68:765-83. doi:10.1007/s00018-010-0567-4. PMID:21072676</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-010-0567-4</ArticleId>
            <ArticleId IdType="pubmed">21072676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Rodriguez A, Mayoral R, Agra N, Valdecantos MP, Pardo V, Miquilena-Colina ME, Vargas-Castrillón J, Lo Iacono O, Corazzari M, Fimia GM, et al.. 
Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 2014;5:e1179. doi:10.1038/cddis.2014.162</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2014.162</ArticleId>
            <ArticleId IdType="pmc">PMC4001315</ArticleId>
            <ArticleId IdType="pubmed">24743734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wree A, McGeough MD, Pena CA, Schlattjan M, Li H, Inzaugarat ME, Messer K, Canbay A, Hoffman HM, Feldstein AE, et al.. 
NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berlin, Germany). 2014;92:1069-82. doi:10.1007/s00109-014-1170-1. PMID:24861026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00109-014-1170-1</ArticleId>
            <ArticleId IdType="pmc">PMC4349416</ArticleId>
            <ArticleId IdType="pubmed">24861026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altmann SW, Davis HR, Jr Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al.. 
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Sci (New York, NY). 2004;303:1201-4. doi:10.1126/science.1093131</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1093131</ArticleId>
            <ArticleId IdType="pubmed">14976318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SW.
Intestinal and hepatic niemann-pick c1-like 1. Diabetes Metab J. 2013;37:240-8. doi:10.4093/dmj.2013.37.4.240</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4093/dmj.2013.37.4.240</ArticleId>
            <ArticleId IdType="pmc">PMC3753488</ArticleId>
            <ArticleId IdType="pubmed">23991401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, et al.. 
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101-7. doi:10.1007/s00535-010-0291-8. PMID:20658156</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-010-0291-8</ArticleId>
            <ArticleId IdType="pubmed">20658156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, et al.. 
Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res Official J Japan Society Hepatol. 2010;40:566-73. doi:10.1111/j.1872-034X.2010.00644.x. PMID:20412324</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1872-034X.2010.00644.x</ArticleId>
            <ArticleId IdType="pubmed">20412324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamura T, Ohsaki Y, Suzuki M, Shinohara Y, Tatematsu T, Cheng J, Okada M, Ohmiya N, Hirooka Y, Goto H, et al.. 
Inhibition of Niemann-Pick-type C1-like1 by ezetimibe activates autophagy in human hepatocytes and reduces mutant alpha1-antitrypsin Z deposition. Hepatology (Baltimore, Md). 2014;59:1591-9. doi:10.1002/hep.26930. PMID:24214142</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26930</ArticleId>
            <ArticleId IdType="pubmed">24214142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al.. 
TFEB links autophagy to lysosomal biogenesis. Science (New York, NY). 2011;332:1429-33. doi:10.1126/science.1204592</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1204592</ArticleId>
            <ArticleId IdType="pmc">PMC3638014</ArticleId>
            <ArticleId IdType="pubmed">21617040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mihaylova MM, Shaw RJ. 
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13:1016-23. doi:10.1038/ncb2329. PMID:21892142</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2329</ArticleId>
            <ArticleId IdType="pmc">PMC3249400</ArticleId>
            <ArticleId IdType="pubmed">21892142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. 
Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochemical Pharmacol. 2012;83:385-94. doi:10.1016/j.bcp.2011.11.008. PMID:22120676</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2011.11.008</ArticleId>
            <ArticleId IdType="pubmed">22120676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferron M, Settembre C, Shimazu J, Lacombe J, Kato S, Rawlings DJ, Ballabio A, Karsenty G. 
A RANKL-PKCbeta-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts. Genes Dev. 2013;27:955-69. doi:10.1101/gad.213827.113</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.213827.113</ArticleId>
            <ArticleId IdType="pmc">PMC3650231</ArticleId>
            <ArticleId IdType="pubmed">23599343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Werneburg NW, Charlton MR, Shah VH, Malhi H, Gores GJ, et al.. 
Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology. 2016;150:956-67. doi:10.1053/j.gastro.2015.12.037. PMID:26764184</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2015.12.037</ArticleId>
            <ArticleId IdType="pmc">PMC4808464</ArticleId>
            <ArticleId IdType="pubmed">26764184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore MN, Allen JI, McVeigh A, Shaw J. 
Lysosomal and autophagic reactions as predictive indicators of environmental impact in aquatic animals. Autophagy. 2006;2:217-20. PMID:16874099. doi:10.4161/auto.2663</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/auto.2663</ArticleId>
            <ArticleId IdType="pubmed">16874099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahishali E, Demir K, Ahishali B, Akyuz F, Pinarbasi B, Poturoglu S, Ibrisim D, Gulluoglu M, Ozdil S, Besisik F, et al.. 
Electron microscopic findings in non-alcoholic fatty liver disease: is there a difference between hepatosteatosis and steatohepatitis?
J Gastroenterol Hepatol. 2010;25:619-26. PMID:20370732. doi:10.1111/j.1440-1746.2009.06142.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1746.2009.06142.x</ArticleId>
            <ArticleId IdType="pubmed">20370732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. 
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology (Baltimore, Md). 2011;54:133-44. PMID:21488066</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4158408</ArticleId>
            <ArticleId IdType="pubmed">21488066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardie DG, Ross FA, Hawley SA. 
AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251-62. doi:10.1038/nrm3311. PMID:22436748</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3311</ArticleId>
            <ArticleId IdType="pmc">PMC5726489</ArticleId>
            <ArticleId IdType="pubmed">22436748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Settembre C, De Cegli R Mansueto G, Saha PK, Vetrini F, Visvikis O, Huynh T, Carissimo A, Palmer D, Klisch TJ, et al.. 
TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol. 2013;15:647-58. doi:10.1038/ncb2718. PMID:23604321</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2718</ArticleId>
            <ArticleId IdType="pmc">PMC3699877</ArticleId>
            <ArticleId IdType="pubmed">23604321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, Huynh T, Ferron M, Karsenty G, Vellard MC, et al.. 
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31:1095-108. doi:10.1038/emboj.2012.32. PMID:22343943</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emboj.2012.32</ArticleId>
            <ArticleId IdType="pmc">PMC3298007</ArticleId>
            <ArticleId IdType="pubmed">22343943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KH, Lee MS. 
Autophagy–a key player in cellular and body metabolism. Nat Rev Endocrinol. 2014;10:322-37. doi:10.1038/nrendo.2014.35. PMID:24663220</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrendo.2014.35</ArticleId>
            <ArticleId IdType="pubmed">24663220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salminen A, Kaarniranta K, Kauppinen A. 
Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging. 2012;4:166-75. doi:10.18632/aging.100444. PMID:22411934</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/aging.100444</ArticleId>
            <ArticleId IdType="pmc">PMC3348477</ArticleId>
            <ArticleId IdType="pubmed">22411934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen H, Ting JP, O'Neill LA. 
A role for the NLRP3 inflammasome in metabolic diseases–did Warburg miss inflammation?
Nat Immunol. 2012;13:352-7. doi:10.1038/ni.2228. PMID:22430788</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2228</ArticleId>
            <ArticleId IdType="pmc">PMC4090390</ArticleId>
            <ArticleId IdType="pubmed">22430788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin L, Yang YB, Yang YX, Zhu N, Li SX, Liao DF, , Zheng XL.
Anti-inflammatory activity of ezetimibe by regulating NF-kappaB/MAPK pathway in THP-1 macrophages. Pharmacology. 2014;93:69-75. doi:10.1159/000357953. PMID:24557496</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000357953</ArticleId>
            <ArticleId IdType="pubmed">24557496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato K, Meng F, Glaser S, Alpini G. 
Exosomes in liver pathology. J Hepatol. 2016;65:213-21. doi:10.1016/j.jhep.2016.03.004. PMID:26988731</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2016.03.004</ArticleId>
            <ArticleId IdType="pmc">PMC4912847</ArticleId>
            <ArticleId IdType="pubmed">26988731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G. 
Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology (Baltimore, Md). 2012;56:1946-57. doi:10.1002/hep.25873. PMID:22684891</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.25873</ArticleId>
            <ArticleId IdType="pmc">PMC3486954</ArticleId>
            <ArticleId IdType="pubmed">22684891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Povero D, Feldstein AE. Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. Diabetes Metab J. 2016;40:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4768045</ArticleId>
            <ArticleId IdType="pubmed">26912150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kornek M, Lynch M, Mehta SH, Lai M, Exley M, Afdhal NH, Schuppan D. 
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology. 2012;143:448-58. doi:10.1053/j.gastro.2012.04.031. PMID:22537612</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2012.04.031</ArticleId>
            <ArticleId IdType="pmc">PMC3404266</ArticleId>
            <ArticleId IdType="pubmed">22537612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K, Misu H, Ota T, Nakamura M, Yamada K, et al.. 
The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 2014;57:878-90. doi:10.1007/s00125-013-3149-9. PMID:24407920</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00125-013-3149-9</ArticleId>
            <ArticleId IdType="pubmed">24407920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Rooyen DM, Gan LT, Yeh MM, Haigh WG, Larter CZ, Ioannou G, Teoh NC, Farrell GC. 
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. Journal of Hepatology. 2013;59:144-52. doi:10.1016/j.jhep.2013.02.024. PMID:23500152</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2013.02.024</ArticleId>
            <ArticleId IdType="pubmed">23500152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee DH, Han DH, Nam KT, Park JS, Kim SH, Lee M, Kim G, Min BS, Cha BS, Lee YS, et al.. 
Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radical Biol Med. 2016;99:520-32. doi:10.1016/j.freeradbiomed.2016.09.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2016.09.009</ArticleId>
            <ArticleId IdType="pubmed">27634173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burnett DA, Caplen MA, Davis HR Jr, Burrier RE, Clader JW. 
2-Azetidinones as inhibitors of cholesterol absorption. J Med Chem. 1994;37:1733-6. doi:10.1021/jm00038a001. PMID:8021912</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm00038a001</ArticleId>
            <ArticleId IdType="pubmed">8021912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salisbury BG, Davis HR, Burrier RE, Burnett DA, Bowkow G, Caplen MA, Clemmons AL, Compton DS, Hoos LM, McGregor DG, et al.. 
Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. Atherosclerosis. 1995;115:45-63. doi:10.1016/0021-9150(94)05499-9. PMID:7669087</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0021-9150(94)05499-9</ArticleId>
            <ArticleId IdType="pubmed">7669087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, et al.. 
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102:8132-7. doi:10.1073/pnas.0500269102. PMID:15928087</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0500269102</ArticleId>
            <ArticleId IdType="pmc">PMC1149415</ArticleId>
            <ArticleId IdType="pubmed">15928087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi Y, Fukusato T. 
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:15539-48. doi:10.3748/wjg.v20.i42.15539. PMID:25400438</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i42.15539</ArticleId>
            <ArticleId IdType="pmc">PMC4229519</ArticleId>
            <ArticleId IdType="pubmed">25400438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seglen PO.
Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J Toxicol Environmental Health. 1979;5:551-60. doi:10.1080/15287397909529766. PMID:224209</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15287397909529766</ArticleId>
            <ArticleId IdType="pubmed">224209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song YM, Lee YH, Kim JW, Ham DS, Kang ES, Cha BS, Lee HC, Lee BW. 
Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway. Autophagy. 2015;11:46-59. doi:10.4161/15548627.2014.984271. PMID:25484077</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/15548627.2014.984271</ArticleId>
            <ArticleId IdType="pmc">PMC4502778</ArticleId>
            <ArticleId IdType="pubmed">25484077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang HJ, Park JY, Kwon O, Choe EY, Kim CH, Hur KY, Lee MS, Yun M, Cha BS, Kim YB, et al.. 
Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction. Autophagy. 2015;11:2089-101. doi:10.1080/15548627.2015.1091139. PMID:26389569</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2015.1091139</ArticleId>
            <ArticleId IdType="pmc">PMC4824590</ArticleId>
            <ArticleId IdType="pubmed">26389569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruwart MJ, Rush BD, Snyder KF, Peters KM, Appelman HD, Henley KS. 
16,16-Dimethyl prostaglandin E2 delays collagen formation in nutritional injury in rat liver. Hepatol (Baltimore, Md). 1988;8:61-4. doi:10.1002/hep.1840080112. PMID:3338720</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.1840080112</ArticleId>
            <ArticleId IdType="pubmed">3338720</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
